Categories Earnings, Technology

Smart Global Holdings (NASDAQ: SGH): Q1 2020 Earnings Snapshot

— Smart Global Holdings (NASDAQ: SGH) reported its first-quarter 2020 adjusted earnings of $0.55 per share versus $0.73 per share expected.

— Net sales plunged by 31% to $272 million versus $280.02 million expected.

Earnings Update by AlphaStreet

— The GAAP earnings dipped by 99% as its high performance computing business, Penguin Computing, experienced worse than expected seasonal weakness.

— In Brazil, having completed the first full quarter under the new points-based system for local manufacturing, the company is encouraged by the results with units and revenues increased from the previous quarter.

— Looking ahead into the second quarter, the company expects earnings of $0.09-0.19 per share on a GAAP basis and $0.45-0.55 per share on an adjusted basis. The consensus estimates EPS of $0.58 per share.

— Sales are predicted to be in the range of $265-275 million. This is better than the analysts’s view of $270.53 million for the second quarter.

— Looking forward, the company continues to see improvement in its Memory related businesses and expects its second-quarter to be the low point in this market.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Agentforce in focus as Salesforce (CRM) gets ready for Q3 2025 earnings

After delivering mixed results in the first half, Salesforce, Inc. (NYSE: CRM) looks poised to report strong numbers when it publishes third-quarter results next week. The Customer relationship management platform

What to look for when Dollar Tree (DLTR) reports Q3 2024 earnings

Shares of Dollar Tree, Inc. (NASDAQ: DLTR) rose over 5% on Monday. The stock has dropped 27% over the past three months. The discount store chain is scheduled to report

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top